Using IMIDS and PIs to Treat at First Relapse | Paul Richardson, MD | IMS 2023

Using IMIDS and PIs to Treat at First Relapse | Paul Richardson, MD | IMS 2023
IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023
A Comparative Study of Disparities in Myeloma Treatment Access | Matthew Leblanc, PHD, RN | IMS 2023
Managing CART-Cell Therapy in the Real World | Yi Lin, MD, PhD | IMS 2023
Results from the GMMG Concept Trial in Germany | Lisa Leypoldt, MD | IMS 2023
Changes in Weight in Induction Therapy | Ross Firestone, MD, PhD | IMS 2023
Charting the Genetic Evolution of Myeloma Cells | Faith Davies, MD | IMS 2023
Individualizing Frontline Treatment to Get the Best Outcomes | Xavier Leleu, MD, PhD | IMS 2023
Serial MRD Assessments as a Surrogate for Long Term PFS | Frits van Rhee, MD | IMS 2023
Managing Renal Failure | Efstathious Kastritis, MD | IMS 2023
Key Take Aways from IMS 2023 | Rafael Fonseca, MD | IMS 2023
Impact of Racial Disparities in Myeloma | Doctors Cole and Kumar | IMS 2023
Update from IMS on Novel Technologies in Multiple Myeloma | Gareth Morgan, MD, PhD | IMS 2023
Monoclonal Gammopathy of Unknown Significance | Urvi Shah, MD | IMS 2023
Using a Single Cell Approach to Define Mechanisms of Progression | Irene Ghobrial, MD | IMS 2023